Alzheimer's disease research, amyloid plaques, tau tangles, and cognitive decline
410 articles
Specific AQP4 genetic variants alter glymphatic drainage efficiency, directly influencing motor symptom severity and progression in early Parkinson's disease.
A landmark RCT tests whether hearing aids can protect brain health in 977 older adults over 3 years.
A landmark multicohort proteomics study reveals how APOE2 and APOE4 shape Alzheimer's risk through entirely distinct molecular mechanisms.
A completed trial tests EGCG combined with diet, exercise, and cognitive training to slow decline in ApoE4 carriers with early warning signs.
A master autophagy regulator drops with age and in AD patients — restoring it in mice clears amyloid, reduces tau, and rescues cognition.
Scientists used stem cell-derived vesicles to deliver light-activated gene therapy to the brain without surgery, reversing cognitive decline in Alzheimer's mice.
A bibliometric analysis of 595 papers maps how glymphatic-Alzheimer's research has grown exponentially, pinpointing AQP4, sleep, and DTI-ALPS imaging as the hottest frontiers.
Cerebral hypoperfusion drives glymphatic dysfunction in systemic inflammation — and restoring blood flow with levosimendan reverses it.
A completed RCT tests whether treating insomnia with CBT-I can improve cognition and slow amyloid buildup in adults aged 60–85.
Boosting BNIP3 in muscle tissue extends fly lifespan and shields the brain from age-related degeneration via a muscle-brain signaling axis.
A major review reveals how the glymphatic system's failure drives neurodegeneration and brain tumor resistance — and how to fix it.
Blocking brain lymphatic drainage triggers age-dependent compensatory responses — young rats adapt, middle-aged rats largely cannot, with proteomic signs of neurodegeneration in both.
